dc.contributor.author | Ariza-Vioque, E. | |
dc.contributor.author | Ello, F. | |
dc.contributor.author | Andriamamonjisoa, H. | |
dc.contributor.author | Machault, V. | |
dc.contributor.author | Gonza´lez-Martın, J. | |
dc.contributor.author | Calvo-Cortes, M. C. | |
dc.contributor.author | Eholie, S. | |
dc.contributor.author | Tchabert, G. A. | |
dc.contributor.author | Ouassa, T. | |
dc.contributor.author | Raberahona, M. | |
dc.contributor.author | Rakotoarivelo, R. | |
dc.contributor.author | Razafindrakoto, H. | |
dc.contributor.author | Rahajamanana, L. | |
dc.contributor.author | Wilkinson, R. J. | |
dc.contributor.author | Davis, A. | |
dc.contributor.author | Maxebengula, M. | |
dc.contributor.author | Abrahams, F. | |
dc.contributor.author | Muzoora, Conrad | |
dc.contributor.author | Nakigozi, N. | |
dc.contributor.author | Nyehangane, D. | |
dc.contributor.author | Nanjebe, D. | |
dc.contributor.author | Mbega, H. | |
dc.contributor.author | Kaitano, R. | |
dc.contributor.author | Bonnet, M. | |
dc.contributor.author | Debeaudrap, P. | |
dc.contributor.author | Miro´, J. M. | |
dc.contributor.author | Anglaret, X. | |
dc.contributor.author | Rakotosamimanana, N. | |
dc.contributor.author | Calmy, A. | |
dc.contributor.author | Bonnet, F. | |
dc.contributor.author | Ambrosioni, J. | |
dc.contributor.author | INTENSE-TBM Group | |
dc.date.accessioned | 2023-01-31T12:58:01Z | |
dc.date.available | 2023-01-31T12:58:01Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Ariza-Vioque, E., Ello, F., Andriamamonjisoa, H., Machault, V., Gonzalez-Martin, J., Calvo-Cortes, M. C., ... & INTENSE-TBM Group. (2022). Capacity building in Sub-Saharan Africa as part of the INTENSE-TBM project during the COVID-19 pandemic. Infectious Diseases and Therapy, 11(4), 1327-1341. | en_US |
dc.identifier.uri | http://ir.must.ac.ug/xmlui/handle/123456789/2730 | |
dc.description.abstract | Tuberculous meningitis (TBM) is the most severe and disabling form of tuberculosis (TB), with at least 100,000 cases per year and a mortality rate of up to 50% in individuals co-infected with human immunodeficiency virus type 1 (HIV-1). To evaluate the efficacy and safety of an intensified antitubercular regimen and an anti-inflammatory treatment, the INTENSE-TBM project includes a phase III randomised clinical trial (TBM-RCT) in four countries in sub-Saharan Africa (SSA). Within this framework, we designed a comprehensive capacity-building work package ensuring all centres had, or would acquire, the ability to conduct the TBM-RCT and developing a network of skilled researchers, clinical centres and microbiology laboratories. Here, we describe these activities, identify strengths/challenges and share tools adaptable to other projects, particularly inlow-and lower-middle income countries with heterogeneous settings and during the coronavirus disease 2019 (COVID-19) pandemic. Despite major challenges, TBM-RCT initiation was achieved in all sites, promoting enhanced local healthcare systems and encouraging further clinical research in SSA. In terms of certified trainings, the achievement levels were 95% (124/131) for good clinical practice, 91% (39/43) for good clinical laboratory practice and 91% (48/53) for infection prevention and control. Platform-based research, developed as part of capacity-building activities for specific projects, may be a valuable tool in fighting future infectious diseases and in developing high-level research in Africa. | en_US |
dc.description.sponsorship | European Union (Grant RIA2017T-2019) and is sponsored by Inserm–ANRS (ANRS 12398 INTENSE-TBM). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Infectious Diseases and Therapy | en_US |
dc.subject | Africa | en_US |
dc.subject | Capacity building | en_US |
dc.subject | Clinical research | en_US |
dc.subject | HIV | en_US |
dc.subject | INTENSE-TBM | en_US |
dc.subject | Tuberculous meningitis | en_US |
dc.title | Capacity Building in Sub-Saharan Africa as Part of the INTENSE-TBM Project During the COVID-19 Pandemic | en_US |
dc.type | Article | en_US |